1. Home
  2. CCK vs JAZZ Comparison

CCK vs JAZZ Comparison

Compare CCK & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crown Holdings Inc.

CCK

Crown Holdings Inc.

HOLD

Current Price

$100.92

Market Cap

11.4B

Sector

Industrials

ML Signal

HOLD

Logo Jazz Pharmaceuticals plc (Ireland)

JAZZ

Jazz Pharmaceuticals plc (Ireland)

HOLD

Current Price

$182.34

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCK
JAZZ
Founded
1906
2003
Country
United States
Ireland
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.4B
10.4B
IPO Year
2003
2007

Fundamental Metrics

Financial Performance
Metric
CCK
JAZZ
Price
$100.92
$182.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
15
13
Target Price
$122.67
$216.92
AVG Volume (30 Days)
845.2K
937.7K
Earning Date
04-27-2026
05-05-2026
Dividend Yield
1.06%
N/A
EPS Growth
79.72
N/A
EPS
6.38
N/A
Revenue
$11,665,000,000.00
$1,618,693,000.00
Revenue This Year
$5.26
$6.17
Revenue Next Year
$2.40
$7.66
P/E Ratio
$15.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$75.98
$95.49
52 Week High
$116.62
$198.00

Technical Indicators

Market Signals
Indicator
CCK
JAZZ
Relative Strength Index (RSI) 35.12 54.60
Support Level $98.85 $176.67
Resistance Level $102.09 $182.99
Average True Range (ATR) 2.41 4.96
MACD -1.01 -0.92
Stochastic Oscillator 17.93 41.56

Price Performance

Historical Comparison
CCK
JAZZ

About CCK Crown Holdings Inc.

Crown Holdings Inc is a producer of metal packaging. The company manufactures beverage cans, metal food cans, and closures, as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: